Pyramid Research

Pyramid Biosciences is a clinical-stage biotechnology company dedicated to developing a portfolio of precision therapies for patients with cancer and other molecularly defined diseases. The company's lead oncology program, PBI-200, is a next-generation, highly CNS-penetrant TRK inhibitor currently in a global Phase 1/2 clinical trial for patients with NTRK-fusion driven cancers, including primary and metastatic brain tumors. Pyramid has also expanded its pipeline through a strategic in-licensing agreement for GQ1010, a potential best-in-class TROP2-targeted antibody-drug conjugate (ADC) designed to offer an improved therapeutic margin. Headquartered in Waltham, Massachusetts, the company focuses on targeting clinically validated mechanisms with best-in-class potential to address significant unmet needs in oncology.